-308 G > A of TNF-α gene promoter decreases the risk of multiple sclerosis: A meta-analysis

Multiple Sclerosis Journal

Volumn 17, Issue 6, 2011, Pages 658-665

  Yang, Yan ^a   Sun, Rulin ^a   Yang, Heng ^a   Zheng, Fang ^a   Gong, Feili ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

gene polymorphism; meta analysis; multiple sclerosis; tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL TRIAL; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEREDITY; HOMOZYGOTE; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; PROMOTER REGION;

EID: 79959483148     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510394009     Document Type: Article

References (36)

1. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001 ; 14: 271-278 (Pubitemid 32510589)
2. Lincoln JA, Cook SD. An overview of gene-epigenetic-environmental contributions to MS causation. J Neurol Sci. 2009 ; 286: 54-57
3. Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009 ; 21: 328-333
4. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res. 1996 ; 45: 322-333 (Pubitemid 26299587)
5. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992 ; 10: 411-452
6. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 ; 94: 3195-3199 (Pubitemid 27157287)
7. Izad M, Vodjgani M, Niknam MH, et al. Cytokines genes polymorphisms and risk of multiple sclerosis. Am J Med Sci. 2010 ; 339: 327-331
8. Ristic S, Lovrecic L, Starcevic-Cizmarevic N, et al. Tumor necrosis factor-alpha-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur Neurol. 2007 ; 57: 203-207 (Pubitemid 46701476)
9. Kamali-Sarvestani E, Nikseresht A, Aflaki E, Sarvari J, Gharesi-Fard B. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol Scand. 2007 ; 115: 161-166 (Pubitemid 46219208)
10. Forte GI, Ragonese P, Salemi G, et al. Search for genetic factors associated with susceptibility to multiple sclerosis. Ann N Y Acad Sci. 2006 ; 1067: 264-269 (Pubitemid 43806333)
11. Mihailova S, Ivanova M, Mihaylova A, Quin L, Mikova O, Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol. 2005 ; 168: 138-143 (Pubitemid 41396411)
12. Luomala M, Lehtimaki T, Huhtala H, et al. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand. 2003 ; 108: 396-400 (Pubitemid 37464118)
13. Drulovic J, Popadic D, Mesaros S, et al. Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. Eur Neurol. 2003 ; 50: 25-29 (Pubitemid 36736966)
14. Fernandes Filho JA, Vedeler CA, Myhr KM, Nyland H, Pandey JP. TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity. 2002 ; 35: 377-380 (Pubitemid 35252228)
15. Fernandez-Arquero M, Arroyo R, Rubio A, et al. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology. 1999 ; 53: 1361-1363 (Pubitemid 29480107)
16. Mycko M, Kowalski W, Kwinkowski M, et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol. 1998 ; 84: 198-206 (Pubitemid 28248406)
17. Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology. 1997 ; 49: 626-628 (Pubitemid 27368919)
18. Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol. 1997 ; 72: 149-153 (Pubitemid 27062770)
19. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol. 1995 ; 63: 143-147 (Pubitemid 26020718)
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 ; 21: 1539-1558 (Pubitemid 34746062)
21. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet. 2005 ; 50: 267-275 (Pubitemid 41159982)
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 ; 315: 629-634 (Pubitemid 27387172)
23. Comabella M, Craig DW, Camina-Tato M, et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One. 2008 ; 3: e3490 - e3490
24. Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet. 2007 ; 39: 1108-1113 (Pubitemid 47340654)
25. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007 ; 357: 851-862 (Pubitemid 47347319)
26. Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet. 2007 ; 39: 1083-1091 (Pubitemid 47340652)
27. Hoffjan S, Akkad DA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes. 2010 ; 24: 237-243
28. Bush WS, Sawcer SJ, de Jager PL, et al. Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come. Am J Hum Genet. 2010 ; 86: 621-625
29. Bahreini SA, Jabalameli MR, Saadatnia M, Zahednasab H. The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility. J Neuroimmunol. 2010 ;:
30. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009 ; 41: 776-782
31. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996 ; 47: 1531-1534 (Pubitemid 26422549)
32. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009 ; 45: 55-57
33. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001 ; 57: 1885-1888 (Pubitemid 33096700)
34. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 ; 44: 2862-2869 (Pubitemid 34016206)
35. Siddiqui MA, Scott LJ. Spotlight on infliximab in Crohn disease and rheumatoid arthritis. BioDrugs. 2006 ; 20: 67-70
36. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999 ; 53: 457-465